Apex Laboratories Pvt. Ltd., a pharmaceutical company based in Chennai, announced Tuesday the launch of an advanced form of Itraconazole Capsules Supra Bioavailable 65 and 130mg, a potent therapeutic choice to effectively fight fungal infections.
According to the company’s Supra Bioavailable Itraconazole Capsules, a higher percentage (90%) of the active drug is delivered to the biological system, at a lower dose. This advanced preparation also reduces inter-individual variability, which could translate into improved efficacy in the treatment of fungal infections.
Superficial mycoses of skin, nails and hair are among the most common fungal infections and the World Health Organization (WHO) reported their prevalence rate of 25 percent and it varies for occupational groups, gender and age groups. Itraconazole capsule has become an oral treatment of choice for superficial fungal diseases, the company claims. “Itraconazole is also considered a first-line treatment in many countries for treating infections such as sporotrichosis, histoplasmosis, blastomycosis and cryptococcosis that circulate throughout the body, the report said.
“While Itraconazole is an effective agent for fungal infections, studies state that it has limitations, such as poor absorption and variability in blood concentrations, and for any drug to produce a desired clinical effect, its absorption must be optimal with minimal inter-individual variability. Vishagan Sulur Vanangamudi, Director of Apex Laboratories Pvt. Ltd said in a statement.
The United States Food and Drug Administration (USFDA) has approved the SUBA (Super Bio-Available) preparation of Itraconazole 65 mg and 130 mg capsules. In India, the Central Drugs Standard Control Organization (CDSCO) also approved the similar formulation of Supra Bioavailable Itraconazole 65 & 130mg Capsules for the treatment of blastomycosis, histoplasmosis and aspergillosis.
“Supra Bioavailable Itraconazole 65 & 130mg Capsules are prepared using Top spray granulation technology which is used to improve the dissolution rate of Itraconazole. It contains a solid dispersion of Itraconazole in a uniform non-pellet formulation. This new technology improves the bioavailability of poorly soluble drugs. The technology uses a solid dispersion of the drug in a polymer to enhance absorption in the gastrointestinal tract to achieve super bioavailability compared to conventional preparations,” added Mr. Vanangamudi.
The pharmaceutical company claims that Supra Bioavailable Itraconazole can be taken with or without food and can be co-administered with drugs that lower stomach acidity without causing any reduction in the absorption of Itraconazole.
